Hepion Pharmaceuticals replaces Grassi with RRBB as auditor amid going-concern doubt and material weaknesses

Hepion Pharmaceuticals, Inc.

Hepion's audit committee approved dismissing Grassi & Co., CPAs, P.C. and engaging Rosenberg Rich Baker Berman P.A. as independent auditor on Sept. 21, 2026.
Grassi was informed on Sept. 22, 2026 of its immediate dismissal; its reports on 2025 and 2024 included an explanatory paragraph about substantial doubt over going concern.
Hepion cited material weaknesses in internal control over financial reporting described in its 2025 and 2024 10-Ks and 10-Qs for March 31 and June 30, 2026.
Hepion reported no disagreements with Grassi on accounting principles, disclosures, or audit scope through Sept. 21, 2026; no RRBB consultations were disclosed.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.